X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (52) 52
oncology (49) 49
humans (48) 48
melanoma (41) 41
middle aged (32) 32
melanoma - drug therapy (29) 29
male (27) 27
female (26) 26
ipilimumab (26) 26
metastatic melanoma (26) 26
aged (24) 24
skin neoplasms - drug therapy (22) 22
adult (20) 20
melanoma - pathology (20) 20
vemurafenib (19) 19
dermatology (18) 18
610 medicine & health (17) 17
metastasis (17) 17
dermatology clinic (16) 16
immunotherapy (15) 15
skin neoplasms - pathology (15) 15
melanoma - genetics (14) 14
mutation (13) 13
antineoplastic agents - therapeutic use (12) 12
nivolumab (12) 12
survival (12) 12
antibodies, monoclonal - therapeutic use (11) 11
care and treatment (11) 11
open-label (11) 11
retrospective studies (11) 11
braf (10) 10
cancer (10) 10
hematology, oncology and palliative medicine (10) 10
metastases (10) 10
pembrolizumab (10) 10
protein kinase inhibitors - therapeutic use (10) 10
proto-oncogene proteins b-raf - genetics (10) 10
skin neoplasms - genetics (10) 10
targeted therapy (10) 10
aged, 80 and over (9) 9
medicine, research & experimental (9) 9
mutations (9) 9
neoplasm staging (9) 9
prognosis (9) 9
programmed cell death 1 receptor - antagonists & inhibitors (9) 9
proto-oncogene proteins b-raf - antagonists & inhibitors (9) 9
safety (9) 9
young adult (9) 9
analysis (8) 8
skin (8) 8
treatment outcome (8) 8
antineoplastic agents - adverse effects (7) 7
braf inhibitor (7) 7
dabrafenib (7) 7
disease progression (7) 7
melanoma - immunology (7) 7
melanoma - therapy (7) 7
neoplasm metastasis (7) 7
patients (7) 7
pd-1 blockade (7) 7
resistance (7) 7
tumors (7) 7
advanced melanoma (6) 6
health aspects (6) 6
immunology (6) 6
melanoma - mortality (6) 6
multicenter (6) 6
protein kinase inhibitors - adverse effects (6) 6
therapy (6) 6
antibodies, monoclonal - adverse effects (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
apoptosis (5) 5
article (5) 5
cell death (5) 5
chemotherapy (5) 5
cutaneous melanoma (5) 5
cytotoxicity (5) 5
immunotherapy - methods (5) 5
melanoma - secondary (5) 5
research (5) 5
toxicity (5) 5
trial (5) 5
anti-pd-1 (4) 4
antibodies (4) 4
antibodies, monoclonal - administration & dosage (4) 4
antibodies, monoclonal, humanized - administration & dosage (4) 4
antibodies, monoclonal, humanized - adverse effects (4) 4
antigens (4) 4
antimitotic agents (4) 4
antineoplastic agents (4) 4
brain neoplasms - secondary (4) 4
cell biology (4) 4
ctla-4 antigen - immunology (4) 4
diagnosis (4) 4
disease-free survival (4) 4
follow-up studies (4) 4
gene mutations (4) 4
improved survival (4) 4
indoles - therapeutic use (4) 4
malignant-melanoma (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Forum Médical Suisse ‒ Swiss Medical Forum, ISSN 1661-6138, 08/2012, Volume 12, Issue 33
Journal Article
Forum Médical Suisse ‒ Swiss Medical Forum, ISSN 1661-6138, 08/2017, Volume 17, Issue 33
Journal Article
Forum Médical Suisse ‒ Swiss Medical Forum, ISSN 1661-6138, 02/2015, Volume 15, Issue 6
Journal Article
Forum Médical Suisse ‒ Swiss Medical Forum, ISSN 1661-6138, 10/2012, Volume 12, Issue 44
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 908 - 918
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2013, Volume 8, Issue 1, pp. e53745 - e53745
Background: Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces... 
REGRESSION | TRIAL | INDUCED SARCOIDOSIS | CTLA-4 BLOCKADE | AUTOIMMUNITY | SAFETY | MULTIDISCIPLINARY SCIENCES | MONOCLONAL-ANTIBODY | PATIENT | HYPOPHYSITIS | CANCER | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Neoplasm Metastasis | Liver - drug effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Endocrine System - drug effects | Adult | Female | Retrospective Studies | Antibodies, Monoclonal - immunology | Kidney - drug effects | Antineoplastic Agents - immunology | Pancreas - drug effects | Gastrointestinal Tract - drug effects | Melanoma - pathology | CTLA-4 Antigen - immunology | Nervous System - drug effects | Melanoma - drug therapy | Respiratory System - drug effects | Aged | Skin - drug effects | Antimitotic agents | Antigens | Care and treatment | Algorithms | Lymphocytes | Melanoma | Skin | Metastasis | Antineoplastic agents | Skin cancer | Cancer | Aseptic meningitis | Guillain-Barre syndrome | Exanthema | Central nervous system | Blocking antibodies | Cytotoxicity | Oncology | Lymphocytes T | Metastases | CTLA-4 protein | Intestine | Gastroenterology | Meningitis | Internal medicine | Hematology | Sarcoidosis | Dermatology | Management | Regression analysis | Patients | Eosinophilia | Morbidity | Inflammatory bowel disease | Pathology | Side effects | Hospitals | Perforations | Medical prognosis | Antitumor activity | Autoimmune diseases | Endocrinology | Index Medicus
Journal Article
Science, ISSN 0036-8075, 10/2015, Volume 350, Issue 6257, pp. 207 - 211
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2013, Volume 50, Issue 3, pp. 611 - 621
Abstract Background & Aim Brain metastases are frequent in patients with metastatic melanoma, indicating poor prognosis. We investigated the BRAF kinase... 
Hematology, Oncology and Palliative Medicine | Vemurafenib | Symptomatic brain metastases | Tumour regression | BRAF inhibitor | Safety | Advanced melanoma | BRAF mutation
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2012, Volume 366, Issue 5, pp. 480 - 481
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 60, pp. 210 - 225
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 60, pp. 190 - 209
Journal Article
Swiss Medical Forum ‒ Schweizerisches Medizin-Forum, ISSN 1424-3784, 08/2017, Volume 17, Issue 33
Journal Article
Cancer Discovery, ISSN 2159-8274, 01/2014, Volume 4, Issue 1, pp. 94 - 109
Journal Article
Journal Article
Journal Article